|View printer-friendly version|
ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines
The article titled “Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells” details the findings of the pre-clinical study in which investigators evaluated the efficacy of varlitinib, a reversible small molecule pan-HER inhibitor, in TNBC. In addition to data previously presented at the
TNBC is a complex disease associated with an aggressive phenotype and poor prognosis, and there are currently no approved therapies for the majority of TNBC patients. TNBC lacks HER2 expression, however it has been reported that other HER receptors are overexpressed. The data from the study show that varlitinib inhibited HER signalling in TNBC cell lines of multiple subtypes (basal-like, mesenchymal-like and luminal androgen receptor) which induced cell apoptosis and reduced cell viability. Varlitinib inhibited pHER3 and pHER4 activation, in addition to pEGFR, in varlitinib-sensitive MDA-MB-468 TNBC cells and suppressed tumour growth in a MDA-MB-468 xenograft mouse model. In one varlitinib-resistant TNBC cell line (MDA-MB-231), varlitinib in combination with either a MEK or ERK inhibitor induced cell apoptosis.
ASLAN has previously reported positive data from a clinical study of varlitinib in patients with HER2 positive metastatic breast cancer. The company is currently investigating varlitinib in global studies in biliary tract cancer.
Media and IR contacts
About varlitinib (ASLAN001)
Forward looking statements
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
Source: ASLAN Pharmaceuticals Limited